Market-cap $57 M --Cash $51 M --Shares Out 13.17 M --Great Pipeline -- Strong Insider & Institutional Ownership -- Phase 2b readout of the COPD trial is imminent (this month ) ,positive results could push this extreme low float stock closer or even above $10 . Unsidocvered and brutally undepriced Stock with massive upside Potential here .GL "We are very pleased that our four-week Phase 2b dose-ranging clinical trial with nebulized ensifentrine is progressing according to plan and that we have completed enrollment of over 400 symptomatic patients with moderate to severe COPD. We anticipate completing this study around the end of 2019." Market-cap $57 M Cash $51 M Price $3.90 Shares Out 13.17 M Presentation (from late November) https://investors.veronapharma.com/static-files/9ed398c4-3150-4c0e-8fe3-1efe276fbffb Insider Buying https://www.lse.co.uk/DirectorsDeals.asp?shareprice=VRP&share=Verona-Pharma Top Shareholders : Vivo Capital, LLC ...1.5M OrbiMed ...1.3M New Enterprise ...1.2M Abingworth ...901.9K VenBio Partners LLC ...875.0K Novo Holdings A/S ...740.7K Andera Partners ...720.9K Aisling Capital ...443.6K Tekla Capital ...275.0K Arctic Fund ...120.4K
